Back to Search
Start Over
Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for Non-small Cell Lung Cancer
- Source :
- Chinese Journal of Lung Cancer, Vol 17, Iss 10, Pp 734-740 (2014)
- Publication Year :
- 2014
- Publisher :
- Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2014.
-
Abstract
- Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get benefit from them. Immunotherapy, through stimulating the body's immune system to improve the antitumor immunity effect, has been a new therapeutic method for non-small cell lung cancer (NSCLC). Study had been reported that immune checkpoint molecules, including programmed death-1 (PD-1)/PD-ligand (L) 1 axis, are closedly related with cancer generation and development, and play a key role on clinical significance of NSCLC. Activation of PD-1/PD-L1 pathway contributes to tumor immune escape, and block PD-1/PD-L1 pathway can enhance endogenous antimuor immunity. Currently increasing clinical trials suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies turned out to be beneficial and safe in NSCLC. Here, we provide a review on the progress of PD-1/PD-L1 pathway and immune checkpoint inhibitors in NSCLC.
Details
- Language :
- Chinese
- ISSN :
- 10093419
- Volume :
- 17
- Issue :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- Chinese Journal of Lung Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.8fed973bdc3842a1adc7ff863e798a48
- Document Type :
- article
- Full Text :
- https://doi.org/10.3779/j.issn.1009-3419.2014.10.05